Clinical Trial Update: Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting [Phase 3]

View source ↗

Summary

This document notes the completion of a Phase 3 trial evaluating Symbicort as a single inhaler therapy for asthma in a general practice setting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Symbicort (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Asthma | Phase 3 | Status: COMPLETED